Enspryng
Enspryng ingredients
| Active ingredient | Strength |
|---|---|
| Satralizumab | 120 mg/mL, 180 mg/1.5mL |
What Enspryng is used for
The FDA lists the approved uses on the official label (below). In the EU, satralizumab is approved as Enspryng for:
Satralizumab (Enspryng) is indicated as a monotherapy or in combination with immunosuppressive therapy (IST) for the treatment of neuromyelitis optica spectrum disorders (NMOSD) in adult and adolescent patients from 12 years of age who are anti-aquaporin-4 IgG (AQP4-IgG) seropositive.
EU wording from the European Medicines Agency; US approved uses can differ.
Key facts
- Brand
- Enspryng
- Generic name
- Satralizumab
- Made by
- Genentech, Inc.
- Forms
- Injection, Solution
- Given
- Subcutaneous
- FDA approval
- Biologic licence (BLA) BLA761149
- On the US market since
- 2020
Official information
- MedlinePlus drug information (search for Satralizumab)
Specialist medicine: started and supervised by a specialist doctor or hospital. This page is a plain-language summary of public official information, not medical advice; follow your doctor and the official product information.
Common questions
What is Enspryng?
Enspryng (Satralizumab) is a specialist medicine made by Genentech, Inc., approved by the US FDA.
What are the ingredients of Enspryng?
Enspryng contains Satralizumab (120 mg/mL, 180 mg/1.5mL).
Is Enspryng approved in Europe?
The same active substance is approved in the EU as Enspryng.
From the FDA National Drug Code directory (open.fda.gov, public domain) and the European Medicines Agency medicines list. Page made 5 November 2026 by Satya Babu.
← All specialty medicines, USA